Millendo Therapeutics with ticker code (MLND) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The range between the high target price and low target price is between 5 and 2 calculating the average target price we see 4. Now with the previous closing price of 2.25 this is indicating there is a potential upside of 77.8%. The day 50 moving average is 1.79 and the 200 moving average now moves to 1.79. The market capitalisation for the company is $43m. Find out more information at: http://www.millendo.com
Millendo Therapeutics, a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.